Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2019

01-06-2019 | Liver Transplantation | Hepatitis C (H Vargas and S Flamm, Section Editors)

The Use of Grafts from HCV+ Patients in Transplantation: Are we There Yet?

Authors: Kathy M. Nilles, Steven L. Flamm

Published in: Current Hepatology Reports | Issue 2/2019

Login to get access

Abstract

Use of organs from donors previously or currently infected with hepatitis C virus is gaining interest in the transplantation realm.

Purpose of Review

Here we will outline the historical perspectives for discarding such organs, review the reasons for revitalized interest in their use, and highlight available data on the use of hepatitis C virus (HCV)-viremic grafts in transplantation. We will summarize arguments supporting and against such practices and offer our recommendations.

Recent Findings

HCV can now be safely and effectively treated post transplantation with direct-acting antivirals (DAAs). Several reports are highlighted in which HCV-viremic organ donation was performed, followed by DAA treatment. However, opinions abound on the appropriateness of this practice.

Summary

Use of viremic organs requires further study and additional larger-scale data with longer-term follow-up, but overall appears safe. It is a viable method to expand the donor pool in both liver and non-liver organ transplantation, but must be carefully weighed with the risks.
Literature
1.
Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Harper AM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18(Suppl 1):172–253.CrossRefPubMed
2.
3.
Nam H, et al. Donor-derived viral infections in liver transplantation. Transplantation. 2018;102(11):1824–36.CrossRefPubMed
4.
Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1188–200.CrossRefPubMedPubMedCentral
5.
• Annambhotla PD, Gurbaxani BM, Kuehnert MJ, Basavaraju SV. A model to estimate the probability of human immunodeficiency virus and hepatitis C infection despite negative nucleic acid testing among increased-risk organ donors. Transpl Infect Dis. 2017;19(2) The risk of transmission of HCV during the eclipse period is 0.3 to 3% depending on donor behavior.
6.
7.
Pereira BJ, et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325(7):454–60.CrossRefPubMed
8.
Pereira BJ, et al. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet. 1995;345(8948):484–7.CrossRefPubMed
9.
Berenguer M, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32(4 Pt 1):852–8.CrossRefPubMed
10.
Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103(1):317–22.CrossRefPubMed
11.
Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42(2):255–62.CrossRefPubMed
12.
Tekin F, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther. 2008;27(11):1081–5.CrossRefPubMed
13.
Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148(1):100–107 e1.CrossRefPubMed
14.
Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant. 2010;15(3):301–9.CrossRefPubMed
15.
Samuel D, Feray C. Recurrence of hepatitis C virus infection after liver transplantation. J Hepatol. 1999;31(Suppl 1):217–21.CrossRefPubMed
16.
Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant. 2014;14(5):994–1002.CrossRefPubMed
17.
Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32(4):673–84.CrossRefPubMed
18.
Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29(1):250–6.CrossRefPubMed
19.
Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15(9):1063–71.CrossRefPubMed
20.
Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12(8):1192–204.CrossRefPubMed
21.
Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142(6):1373–1383 e1.CrossRefPubMed
22.
Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl. 2007;13(5):719–24.CrossRefPubMed
23.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889–96.CrossRefPubMed
24.
Carrion JA, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132(5):1746–56.CrossRefPubMed
25.
Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015;35(11):2433–41.CrossRefPubMed
26.
Picciotto FP, Tritto G, Lanza AG, Addario L, de Luca M, di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46(3):459–65.CrossRef
27.
Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8(3):679–87.CrossRefPubMed
28.
Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American Society of Transplantation consensus conference on the use of hepatitis C Viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790–802.CrossRefPubMed
29.
Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet. 1995;345(8948):469–70.CrossRefPubMed
30.
Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3(9):1167–72.CrossRefPubMed
31.
Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23(10):1038–44.CrossRefPubMed
32.
• Bowring MG, Kucirka LM, Massie AB, Luo X, Cameron A, Sulkowski M, et al. Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant. 2017;17(2):519–27 HCV-positive liver grafts were previously discarded; they are being increasingly used but still are discarded at a rate nearly double that of non-HCV livers. CrossRefPubMed
33.
Terrault NA, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant recipients. Transplantation. 2017;101(5):956–67.CrossRefPubMed
34.
Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–505.CrossRefPubMedPubMedCentral
35.
Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21(6):823–30.CrossRefPubMedPubMedCentral
36.
Kwo PY, Mantry PS, Coakley E, te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375–82.CrossRefPubMed
37.
Guaraldi G, Rossotti R, Verucchi G, Tavio M, Pasulo L, Beghetto B, et al. Successful pre- and posttransplant Sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection. Open Forum Infect Dis. 2017;4(2):ofx065.CrossRefPubMedPubMedCentral
38.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59.CrossRefPubMed
39.
Vinaixa C, Aguilera V, Blanes M, Maupoey J, Berenguer M, Prieto M. Peritransplant antiviral treatment of human immunodeficiency virus/hepatitis C virus-Coinfected patients. Liver Transpl. 2018;24(10):1476–80.CrossRefPubMed
40.
O'Leary JG, Fontana RJ, Brown K, Burton JR Jr, Firpi-Morell R, Muir A, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017;30(2):196–208.CrossRefPubMed
41.
Antonini TM, Coilly A, Rossignol E, Fougerou-Leurent C, Dumortier J, Leroy V, et al. Sofosbuvir-based regimens in HIV/HCV coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study. Transplantation. 2018;102(1):119–26.CrossRefPubMed
42.
Campos-Varela I, Peters MG, Terrault NA. Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting. Clin Infect Dis. 2015;60(1):108–16.CrossRefPubMed
43.
Londono MC, et al. IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. J Antimicrob Chemother. 2016;71(11):3195–201.CrossRefPubMed
44.
Grant JL, Hawkins C, Brooks H, Palella FJ Jr, Koppe SW, Abecassis MM, et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS. 2016;30(1):93–8.PubMedPubMedCentral
45.
Chen T, Terrault NA. Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant. 2016;21(2):111–9.CrossRefPubMed
46.
Panel A-IHG. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–92.CrossRef
47.
Mousa OY, L.N, Aqel B, et al. Impact of direct-acting antiviral (DAA) for HCV treatment on liver transplant outcomes: a multicenter 15 year experience., in The Liver Meeting: American Association for the Study of Liver Disease. Washington DC: Hepatology; 2017.
48.
Tavio M, Vivarelli M, Menzo S, Gori A, Grossi PA, Marigliano A. Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation. Liver Transpl. 2015;21(10):1327–9.CrossRefPubMed
49.
Donato MF, Monico S, Malinverno F, Aghemo A, Maggioni M, Reggiani P, et al. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int. 2015;35(1):1–4.CrossRefPubMed
50.
Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680–7.CrossRefPubMed
51.
•• Levitsky J, Verna EC, O’Leary JG, Bzowej NH, Moonka DK, Hyland RH, et al. Perioperative Ledipasvir-Sofosbuvir for HCV in liver-transplant recipients. N Engl J Med. 2016;375(21):2106–8 DAAs given on the day of transplantation when viremia is at a nadir are effective enough that only 4 weeks of treatment is needed.CrossRefPubMed
52.
Bari K, Luckett K, Kaiser T, Diwan T, Cuffy M, Schoech MR, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67(5):1673–82.CrossRefPubMed
53.
Shah AP, Cameron A, Singh P, Frank AM, Fenkel JM. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens. Transpl Infect Dis. 2017;19(2).
54.
55.
Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L. Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: time for change. Am J Transplant. 2017;17(11):2863–8.CrossRefPubMed
56.
57.
Goldberg DS, Blumberg E, McCauley M, Abt P, Levine M. Improving organ utilization to help overcome the tragedies of the opioid epidemic. Am J Transplant. 2016;16(10):2836–41.CrossRefPubMedPubMedCentral
58.
Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411–9.CrossRefPubMed
59.
Cholankeril G, Li AA, Dennis BB, Toll AE, Kim D, Bonham CA, et al. Increasing trends in transplantation of hepatitis C virus-positive livers into uninfected recipients. Clin Gastroenterol Hepatol. 2018.
60.
•• Croome KP, Lee DD, Pungpapong S, Keaveny AP, Taner CB. What are the outcomes of declining a public health service increased risk liver donor for patients on the liver transplant waiting list? Liver Transpl. 2018;24(4):497–504. the hazard ratio of turning down an increased-risk donor graft for a liver recipient is high at 2.36.CrossRefPubMed
61.
•• Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, et al. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: a modeling study. Hepatology. 2018;67(6):2085–95 The highest benefit of accepting an HCV-viremic organ is seen in patients with MELD scores of 28 or higher.CrossRefPubMedPubMedCentral
62.
Hoare M, Gelson WTH, Rushbrook SM, Curran MD, Woodall T, Coleman N, et al. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology. 2008;48(6):1737–45.CrossRefPubMedPubMedCentral
63.
Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117(1):149–53.CrossRefPubMed
64.
Ballarin R, Cucchetti A, Spaggiari M, Montalti R, di Benedetto F, Nadalin S, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91(11):1265–72.CrossRefPubMed
65.
Testa G, Goldstein RM, Netto G, Abbasoglu O, Brooks BK, Levy MF, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65(7):925–9.CrossRefPubMed
66.
Marroquin CE, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001;7(9):762–8.CrossRefPubMed
67.
Saab S, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9(10):1053–61.CrossRefPubMed
68.
Lai JC, O'Leary JG, Trotter JF, Verna EC, Brown RS Jr, Stravitz RT, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012;18(5):532–8.CrossRefPubMedPubMedCentral
69.
Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73(4):582–7.CrossRefPubMed
70.
Alvaro E, et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc. 2012;44(6):1475–8.CrossRefPubMed
71.
Burr AT, Li YF, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg. 2011;35(7):1590–5.CrossRefPubMed
72.
Takeichi T, et al. Liver transplant from an ABO-incompatible and hepatitis C antibody-positive but an HCV-RNA negative living donor in a familial amyloid polyneuropathy patient. Exp Clin Transplant. 2013;11(2):182–5.CrossRefPubMed
73.
Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyó JM. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant. 2013;13(10):2773–4.CrossRefPubMed
74.
Tokumoto T, Tanabe K, Simizu T, Shimmura H, Iizuka J, Ishikawa N, et al. Kidney transplantation from a donor who is HCV antibody positive and HCV-RNA negative. Transplant Proc. 2000;32(7):1597–9.CrossRefPubMed
75.
Hidaka M, Takatsuki M, Soyama A, Miyaaki H, Ichikawa T, Nakao K, et al. Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report. J Med Case Rep. 2011;5:276.CrossRefPubMedPubMedCentral
76.
Suryaprasad A, Basavaraju SV, Hocevar SN, Theodoropoulos N, Zuckerman RA, Hayden T, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant. 2015;15(7):1827–35.CrossRefPubMed
77.
Elmasry S, Wadhwa S, Bang BR, Cook L, Chopra S, Kanel G, et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology. 2017;152(3):550–553 e8.CrossRefPubMed
78.
Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006;43(10):1277–83.CrossRefPubMed
79.
Koutsoudakis G, Perez-Del-Pulgar S, Forns X. Occult hepatitis C virus infection: are we digging too deep? Gastroenterology. 2017;152(3):472–4.CrossRefPubMed
80.
McHutchison JG, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002;35(3):688–93.CrossRefPubMed
81.
•• Luckett K, Kaiser TE, Bari K, Safdar K, Schoech MR, Apewokin S, et al. Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients. J Am Coll Surg. 2019;228(4):560–7 5 unexpected HCV transmissions occurred in HCV-Ab positive donors; most were successfully treated with DAAs.CrossRefPubMed
82.
Centers for Disease, C. and Prevention. Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation-Pennsylvania, 2009. Am J Transplant. 2011;11(4):863–5.CrossRef
83.
84.
Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Amer J Transpl 2019(19):1380–7.
85.
Saberi B, Hamilton JP, Durand CM, Li Z, Philosophe B, Cameron AM, et al. Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient. Liver Transpl. 2018;24(1):140–3.CrossRefPubMedPubMedCentral
86.
Cosio FG, Sedmak DD, Henry ML, Haddad CA, Falkenhain ME, Elkhammas EA, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation. 1996;62(8):1054–9.CrossRefPubMed
87.
Lefaucheur C, Loupy A, Vernerey D, Duong-van-Huyen JP, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013;381(9863):313–9.CrossRefPubMed
88.
•• Goldberg DS, Abt PL, Blumberg EA, van Deerlin VM, Levine M, Reddy KR, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394–5 HCV viremic kidneys are being transplanted into non-viremic patients with DAA treatment with excellent graft function.CrossRefPubMed
89.
Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373(4):303–5.CrossRefPubMed
90.
• Trotter PB, Summers DM, Ushiro-Lumb I, Robb M, Bradley JA, Powell J, et al. Use of organs from hepatitis C virus-positive donors for uninfected recipients: a potential cost-effective approach to save lives? Transplantation. 2018;102(4):664–72 Treating HCV in kidney recipients with DAAs is less expensive than an additional five years of remaining on dialysis.CrossRefPubMed
91.
Theodoropoulos N, Whitson BA, Martin SI, Pouch S, Pope-Harman A. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient. Transpl Infect Dis. 2017;19(2).
92.
Moayedi Y, Gulamhusein AF, Ross HJ, Teuteberg JJ, Khush KK. Accepting hepatitis C virus-infected donor hearts for transplantation: multistep consent, unrealized opportunity, and the Stanford experience. Clin Transpl. 2018;32(7):e13308.CrossRef
93.
Woolley AE, Baden LR. Increasing access to thoracic organs from donors infected with hepatitis C: a previous challenge-now an opportunity. J Heart Lung Transplant. 2018;37(5):681–3.CrossRefPubMed
94.
Schlendorf KH, Zalawadiya S, Shah AS, Wigger M, Chung CY, Smith S, et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J Heart Lung Transplant. 2018;37(6):763–9.CrossRefPubMed
95.
Martins PN, Movahedi B, Bozorgzadeh A. Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;377(11):1104–5.PubMed
96.
Wettersten N, Tran H, Mekeel K, Pretorius V, Adler E, Aslam S. Successful heart-kidney transplantation from a hepatitis C viremic donor to negative recipient: one year of follow-up. Transpl Infect Dis. 2019;21(1):e13002.CrossRefPubMed
97.
•• Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533–40 Transplantation of kidneys from HCV viremic donors and treating HCV with DAAs is safe and effective with excellent outcomes.CrossRefPubMedPubMedCentral
98.
Lee GS, Anesi J, Besharatian BD, Bittermann T, Hamel S, Goldberg DS. Con: Use of Hepatitis C Virus-Positive Donors Should be Restricted to Research Protocols. Clin Liver Dis. 2018;12(4):105–8.CrossRef
99.
Goldberg DS, Levitsky J. Transplanting livers from HCV-infected donors into HCV-negative recipients: promise but mind the pitfalls. Amer J Transpl 2019;19(5):1264–5.
100.
Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol. 2017;15(4):584–593 e2.CrossRefPubMed
101.
• Chan C, Schiano T, Agudelo E, Paul Haydek J, Hoteit M, Laurito MP, et al. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. Am J Transplant. 2018;18(10):2506–12 Immune-mediated graft dysfunction including rejection and plasma cell hepatitis has been reported in patients being treated with DAAs.CrossRefPubMed
102.
Campos-Varela I, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, et al. Hepatitis C genotype influences post-liver transplant outcomes. Transplantation. 2015;99(4):835–40.CrossRefPubMedPubMedCentral
103.
Verna EC, Goldberg DS. Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: ready for prime time? Liver Transpl. 2018;24(1):12–4.CrossRefPubMed
104.
Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19(1):78–88.CrossRefPubMed
105.
Siddiqui AR, Abbas Z, Luck NH, Hassan SM, Aziz T, Mubarak M, et al. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transplant Proc. 2012;44(3):721–4.CrossRefPubMed
106.
Wadei HM, Pungpapong S, Cortese C, Alexander MP, Keaveny AP, Yang L, et al. Transplantation of HCV-infected organs into uninfected recipients: advance with caution. Am J Transplant. 2019;19(3):960–1.CrossRefPubMed
107.
Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor Sofosbuvir. Clin Pharmacokinet. 2015;54(7):677–90.CrossRefPubMed
108.
Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015;35(5):281–9.CrossRefPubMedPubMedCentral
109.
Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015;49(6):674–87.CrossRefPubMed
110.
Werbel WA, Durand C. Pro: Use of Hepatitis C Virus-Positive Donors Should Be Considered Standard of Care. Clin Liver Dis. 2018;12(4):100–4.CrossRef
111.
• Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, et al. Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy. Clin Gastroenterol Hepatol. 2019;17(4):739–47 e8. Treatment of patients post liver-transplantation with DAAs who were transplanted with HCV organs is less expensive than remaining on the transplantation waitlist.CrossRefPubMed
112.
Levitsky J, Formica RN. Response to: HCV viremic donors with hepatic bridging fibrosis: are we ready to use their livers in the era of direct-acting antivirals? Am J Transplant. 2017;17(11):2988.CrossRefPubMed
113.
• Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16(1):137 Longterm outcomes of patients who receive “HCV-positive” organs is no different than those who receive “negative” organs.CrossRefPubMedPubMedCentral
114.
Shaffer AA, Thomas AG, Bowring MG, van Pilsum Rasmussen SE, Cash A, Kucirka LM, et al. Changes in practice and perception of hepatitis C and liver transplantation: results of a national survey. Transpl Infect Dis. 2018;20(6):e12982.CrossRefPubMed
Metadata
Title
The Use of Grafts from HCV+ Patients in Transplantation: Are we There Yet?
Authors
Kathy M. Nilles
Steven L. Flamm
Publication date
01-06-2019
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2019
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-019-00466-0

Other articles of this Issue 2/2019

Current Hepatology Reports 2/2019 Go to the issue

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring?

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Portal Hypertension in NASH: Is It Different from Other Aetiologies?

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Management of Fatigue in Primary Biliary Cholangitis

Hepatitis C (H Vargas and S Flamm, Section Editors)

Hepatitis C-Positive Organs for Liver and Kidney Transplantation—Emerging Data and Current Management Strategies

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits